Company intelligence / Profile preview

Shenzhen Kexing Pharmaceutical

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~947
Development stage: Other

Overview

Kexing Biopharm has multiple recombinant biologics and biosimilars approved and marketed in China, including growth hormone, interferon, and interleukin-2; new assets focusing on cancer cachexia and metabolic diseases are progressing through early clinical and IND stages, with innovative modalities including nanobody-Fc fusions[1][2][11].

Therapeutic areas: OncologyInfectious DiseasesEndocrinology
Modalities: Recombinant proteinMonoclonal antibodyNanobody therapySmall moleculeBiologicHormoneVaccine
Industry: Biotech

Drug pipeline

3 assets

GB08

2 more assets in the full pipeline.

Request access →

Partnerships

IQVIA (global clinical development and regulatory strategy partner)[6]

Beyond the preview

Go deeper on Shenzhen Kexing Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Kexing Pharmaceutical.

Explore the full profile